OBJECTIVE -Severe insulin resistance is associated with high morbidity. Identification of severely insulin-resistant patients who have genetic or acquired insulin receptor dysfunction may aid therapeutic decision making; however, onerous diagnostic tests allied to a low frequency of insulin receptor dysfunction often preclude formal diagnosis. Our previous observation of paradoxical hyperadiponectinemia in insulin receptoropathy provides a possible basis for a simpler and cheaper screening test.
P
athology in the insulin receptor underlies at least two forms of extreme insulin resistance, namely those caused by mutations in the receptor or by autoantibodies against the receptor. While clinical features are helpful in distinguishing these syndromes from more common forms of insulin resistance, they are not definitive (1, 2) . Diagnostic laboratory testing for these disorders is cumbersome and, for the most part, not available from commercial resources. A simple and highly specific screening test would therefore be of special utility. We have previously reported that plasma adiponectin is elevated in these receptoropathies in contrast to other forms of severe insulin resistance (3, 4) , and we now formally assess the diagnostic performance of adiponectin as well as IGF binding protein-1 (IGFBP-1) and sex hormonebinding globulin (SHBG), which are both insulin responsive (5, 6) .
RESEARCH DESIGN AND METHODS -All patients had severe insulin resistance, defined as fasting insulin 150 pmol/l or peak insulin on oral glucose tolerance test 1,500 pmol/l in nondiabetic patients. Complete insulin deficiency was defined as an insulin requirement 3 units ⅐ kg Ϫ1 ⅐ day
Ϫ1
. Those with partial ␤-cell decompensation and clinical features including acanthosis nigricans were included at the investigators' discretion. All patients gave informed consent with approval of the local research ethics committee in Cambridge, U.K., or of the institutional review board of the National Institute of Diabetes and Digestive Kidney Diseases. Patients aged Ͻ1 year were excluded. Genetic insulin receptoropathy was defined by homozygous n ϭ 5), compound heterozygous (n ϭ 6), or heterozygous (n ϭ 9) mutations in the insulin receptor gene. All patients had the insulin receptor gene sequenced. Type B insulin resistance was diagnosed on the basis of severe insulin resistance with anti-insulin receptor antibodies, determined by immunoprecipitation of insulin receptor using patient serum followed by immunoblotting (1,7). Anti-insulin receptor antibody assays were undertaken in patients with features suggestive of type B insulin resistance such as rapid onset of severe insulin resistance in adulthood and associated autoimmune disease (1) .
Other patients had severe insulin resistance that was either idiopathic (n ϭ 62) or due to mutations in the genes encoding lamin A/C (n ϭ 15), Akt2 (n ϭ 2), or AGPAT2 (n ϭ 2). Blood was drawn in the fasting state and plasma stored at Ϫ20°C. Insulin and adiponectin dissociation-enhanced lanthanide fluorescence immunoassays (DELFIA) have previously been described (4, 8) . IGFBP-1 was determined using an immunoradiometric assay (Diagnostic Systems Laboratories) and SHBG using an IMMULITE 1,000 solid phase chemiluminescent enzyme immunometric assay (Siemens Medical Solutions Diagnostics).
RESULTS -Adiponectin was assayed in 20 patients with insulin receptor mutations, 14 patients with type B insulin resistance, and 81 patients with other forms of severe insulin resistance. Mean
adiponectin levels were 19.7, 36.1, and 2.4 mg/l, respectively (online appendix 1, available at http://dx.doi.org/10.2337/ dc07-2194). Receiver operating characteristics analysis was then used; i.e., truepositive and false-positive rates of diagnosis of insulin receptoropathy were determined across the adiponectin range. The receiver operating characteristics curve reveals that adiponectin performs outstandingly as a diagnostic test for insulin receptoropathy (Fig. 1A ). An adiponectin level Ͻ7 mg/l in severe insulin resistance has a 97% positive predictive value (PPV) for insulin receptoropathy, whereas a level Ͻ5 mg/l has a 97% negative predictive value (NPV) (Fig. A) . The only patient with insulin receptoropathy and adiponectin Ͻ5 mg/l had morbid obesity and the heterozygous Cys225Ser insulin receptor mutation. This probably represents receptor haploinsufficiency producing severe insulin resistance only in conjunction with obesity and suggests a gray area where adiponectin is a less accurate screening test. Adiponectin Ͻ8 mg/l had a 100% NPV for type B insulin resistance when genetic insulin receptoropathies were excluded. Similar analyses were undertaken for IGFBP-1 and SHBG (Figs. 1B and C, respectively) , suggesting diagnostic thresholds of 20 g/l for IGFBP-1 (PPV for level Ͻ20, 81%; NPV for level Ͻ20, 83%) and 60 nmol/l for SHBG (PPV for level 60, 83%; NPV for level Ͻ60, 75%). Although these analytes are thus of value in discriminating insulin receptoropathy, neither performs as well as adiponectin.
Diagnosis of insulin receptoropathy has several benefits: It allows consideration of immunomodulatory therapy in type B insulin resistance and identification of severe autosomal recessive genetic defects, enabling future antenatal testing. Futhermore, confirming milder autosomal dominant defects permits family screening, often leading to identification of hitherto undiagnosed, severely insulinresistant diabetes in relatives.
There are important caveats, however. The suggested thresholds must only be applied in the context of severe insulin resistance, as ϳ50% of healthy control subjects have adiponectin levels above these values. Moreover, because adiponectin levels are high in healthy infants and the youngest patient with receptoropathy in this report was aged 4 years, the thresholds should not be used to screen for insulin receptoropathy in younger children without further study. Finally, lack of a universal adiponectin reference standard means that there are significant between-assay differences in calibration. Comparison of the autoDELFIA assay used here with a widely used radioimmunoassay (Linco) suggests that values in this report should be multiplied by 1.7 if applied to adiponectin measured using the Linco radioimmunoassay (online appendix 2) and similar comparisons should be undertaken for each different adiponectin assay.
CONCLUSIONS -Assay of plasma adiponectin in patients with severe insulin resistance affords a simple and inexpensive means of discriminating among patients with loss of insulin receptor function, permitting directed genetic or antibody testing. This should facilitate rapid definitive diagnosis in such patients. Plasma IGFBP-1 and SHBG have utility as alternative, although less accurate, diagnostic discriminators.
